U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors.

Kyriakos P Papadopoulos Erkut Hasan BorazanciAlice T ShawRyohei KatayamaYuki ShimizuViola W ZhuThomas Yang SunHeather A Wakelee Russell W MadisonAlexa B SchrockGiorgio SenaldiNaoki NakaoHiroyuki HanzawaMasaya TachibanaTakeshi IsoyamaKenji NakamaruChenhui DengMeijing LiFrank FanQinying ZhaoYanfei GaoTakashi SetoPasi A JänneSai-Hong Ignatius Ou

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Taletrectinib has manageable toxicities at the MTD of 800 mg daily. Preliminary efficacy was observed in patients with crizotinib-refractory ROS1+ NSCLC.

Keyphrases

brain metastases
small cell lung cancer
cell death
dna damage
endothelial cells
reactive oxygen species
physical activity
advanced non small cell lung cancer
induced pluripotent stem cells
pluripotent stem cells